Table 2 Most frequent TEAEs (≥5% of individuals in placebo or overall TAK-653).
From: Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation
Preferred term | Participants, n (%) | |||
|---|---|---|---|---|
Placebo (n = 24) | TAK-653 0.5 mg (n = 24) | TAK-653 6 mg (n = 24) | All TAK-653 (n = 24) | |
Any TEAE | 7 (29.2) | 9 (37.5) | 12 (50.0) | 15 (62.5) |
Somnolence | 2 (8.3) | 3 (12.5) | 3 (12.5) | 6 (25.0) |
Headache | 2 (8.3) | 1 (4.2) | 4 (16.7) | 4 (16.7) |
Nasopharyngitis | 0 | 3 (12.5) | 1 (4.2) | 4 (16.7) |
Oropharyngeal pain | 1 (4.2) | 0 | 2 (8.3) | 2 (8.3) |
Diarrhea | 0 | 1 (4.2) | 1 (4.2) | 2 (8.3) |
Seasonal allergy | 0 | 1 (4.2) | 1 (4.2) | 2 (8.3) |
Fatigue | 2 (8.3) | 0 | 1 (4.2) | 1 (4.2) |
